Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Nierenberg, A. A. Articles by Fava, M. Search for Related Content PubMed Citation Articles by Nierenberg, A. A. Articles by Fava, M. Depression Antidepressants

Timing of Onset of Antidepressant Response With Fluoxetine Treatment

OBJECTIVE: The purpose of this study was to assess the time until onset of antidepressant response with fluoxetine treatment. METHOD: The authors evaluated 182 outpatients with major depression who had a sustained acute response to fluoxetine treatment. The outpatients received 8 weeks of treatment with 20 mg/day of fluoxetine and were assessed biweekly with the 17-item Hamilton Depression Rating Scale. The onset of response was defined as a 30% decrease in score on the Hamilton depression scale that persisted and led to a 50% decrease by week 8. The Kaplan-Meier product limit and Cox regression analysis were used to model the relationship between relevant variables and time until onset of response. RESULTS: The authors found that at weeks 2, 4, and 6, the probabilities of having an onset of response (for responders) were 55.5%, 24.7%, and 9.3%, respectively. The cumulative probabilities of onset of response at each time point were 55.5%, 80.2%, and 89.5%. Neither demographics nor clinical characteristics of depression predicted time until initial response. CONCLUSIONS: These data suggest that more than half of eventual responders to fluoxetine treatment at 8 weeks start to respond by week 2; over 75% start to respond by week 4. Conversely, the lack of onset of response at 4–6 weeks was associated with about a 73%–88% chance that patients would not have an onset of response by 8 weeks.

This article has been cited by other articles:

				I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines J Psychopharmacol, June 1, 2008; 22(4): 343 - 396. [Abstract] [PDF]

				S. H Kennedy Review: Response to SSRIs in unipolar depression occurs in the first week of treatment Evid. Based Ment. Health, August 1, 2007; 10(3): 81 - 81. [Full Text] [PDF]

				A. Tylee and P. Walters Onset of action of antidepressants BMJ, May 5, 2007; 334(7600): 911 - 912. [Full Text] [PDF]

				K. J. Damjanoska, L. D. Van de Kar, G. H. Kindel, Y. Zhang, D. N. D'Souza, F. Garcia, G. Battaglia, and N. A. Muma Chronic Fluoxetine Differentially Affects 5-Hydroxytryptamine2A Receptor Signaling in Frontal Cortex, Oxytocin- and Corticotropin-Releasing Factor-Containing Neurons in Rat Paraventricular Nucleus J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 563 - 571. [Abstract] [Full Text] [PDF]

				S. Y.H. Kim and R. G. Holloway Burdens and Benefits of Placebos in Antidepressant Clinical Trials: A Decision and Cost-Effectiveness Analysis Am J Psychiatry, July 1, 2003; 160(7): 1272 - 1276. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us